Search

everythinglearnresearchcommunity

for

Search:↓

Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

Treatments for hair loss, including Minoxidil, finasteride, and RU58841. The post discusses the potential benefits of Pyrilutamide compared to RU58841 in terms of strength and longevity.

The conversation is about using pyrilutamide and RU58841 as topical solutions to prevent hair loss. Pyrilutamide is considered safer but less potent than RU58841, which some users find effective despite potential side effects like heart palpitations.

The potential release date for results from a phase 2 trial of Pyrilutamide, a hair loss treatment that combines Minoxidil, Finasteride and RU58841. It was agreed that the results are expected to be released in June 2022.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

A user is treating hair loss with 0.5mg Dutasteride three times a week, 5mg oral Minoxidil daily, and topical finasteride and minoxidil, seeing some improvement but insufficient density. They are considering increasing Dutasteride dosage and addressing high estradiol levels, while also trying to quit vaping.

A long-term finasteride user experienced side effects like sexual dysfunction, dry eyes, muscle weakness, and brain fog, which improved when they stopped the medication. They decided to stop finasteride again, questioning if maintaining hair was worth the negative impact on their well-being.

A hair loss treatment plan includes finasteride, dutasteride, RU58841, pyrilutamide, minoxidil, and microneedling to inhibit DHT and promote hair growth. It also recommends supplements like Reishi and Lion’s Mane mushrooms, and a shampoo with ketoconazole, caffeine, and melatonin.

The conversation criticizes the negative attitude towards those concerned about side effects from hair loss treatments like finasteride and minoxidil, or who prefer natural remedies. Specific treatments discussed include finasteride, minoxidil, rosemary oil, and RU58841, with an agreement that finasteride and minoxidil are proven effective.

User has been on finasteride and switched to Dutasteride 6 months ago, using minoxidil, tretinoin, microneedling, and RU-58841, but still experiencing hair loss. Advice given includes waiting 6-18 months for Dutasteride results and checking if it's definitely MPB.

A user's experimentation with various hair loss treatments, including medications and topical applications; as well as their desire to experience unusual sensations through the use of drugs.

KittaLockwood shared progress photos of their boyfriend's hair after 6 months of taking a combination of finasteride, minoxidil, and vitamin supplements prescribed in an Australian subscription service. They received encouraging responses from other users about supporting their significant other through the journey.

Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.

A user experienced severe side effects from finasteride, including mental health issues and physical symptoms, and sought advice on managing post-finasteride syndrome. Suggestions included checking vitamin levels, considering dopamine agonists, and avoiding further psychiatric medications.

Hair loss treatments like GT20029, pyrilutamide, and Follica show promise in 2022. Phase 1 and 2 trials are underway, and new hair growth studies have been published.

Kintor 0.9% is not effective for hair regrowth or thickening and may cause testicle sensitivity. The conversation criticizes the hype around Kintor and discusses the ineffectiveness of pyrilutamide compared to other treatments like RU58841, finasteride, and minoxidil.

Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.

Considering treatments for hair loss, including Minoxidil, Finasteride, RU58841, Fluridil and Pyrilutamide. The user is weighing the risks of taking unapproved medication before it has been mass produced.

The post and conversation are about the high cost and skepticism surrounding pyrilutamide as a hair loss treatment, with comparisons to minoxidil, finasteride, and RU58841. The original poster defends pyrilutamide's effectiveness and criticizes others for dismissing it without proper understanding.

Pyrilutamide is an experimental hair loss treatment, with users discussing its availability and cost from sources like Anagen Inc, Actifolic, and MinoxidilMax. Some users express concerns about product authenticity and suggest waiting for further trial results to assess its safety and effectiveness.

A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.

People are discussing ordering pyrilutamide for hair loss treatment in the US. The treatment is from Kintor's subsidiary company and is available on Amazon.

Upcoming hair loss treatments for those who can't tolerate DHT blockers, focusing on Minoxidil, microneedling, and ketoconazole. Promising treatments include GT20029, PP405, KX-826, and RU58841, though RU58841 may not be safe.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

Kintor Pharmaceutical's KX-826 shows promising results for hair loss treatment. Users discuss the use of anti-androgens like spironolactone and RU58841, noting concerns about concentration and safety.